You are browsing articles on the topic of Electrophysiology Archives - CardioExchange

Avatar of Larry Husten, PHD

Study Suggests Epinephrine for Cardiac Arrest May Be Harmful (1 Dec 2014)

News

Epinephrine has been a cornerstone of therapy during cardiac resuscitation after cardiac arrest because of its well-established ability to stimulate the heart and increase the probability of a return of spontaneous circulation (ROSC). In recent years, however, concerns have been raised that people treated with epinephrine may have worse neurological outcomes following their resuscitation. In…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)

News

Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

AF Patients at Increased Risk for Silent Strokes (3 Nov 2014)

News

The increased risk of stroke in people with atrial fibrillation (AF) is well known, and this stroke risk is, of course, linked to an increased risk of cognitive impairment and dementia. Less well known is that people with AF have an increased risk for cognitive impairment independent of their stroke risk. Now a new study…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Advisory Panel Gives Tepid Support to New Anticoagulant (31 Oct 2014)

News

On Thursday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-1 in favor of approval for Daiichi Sankyo’s edoxaban (Savaysa). The outcome will likely result in a drug that will be on the market, but that few physicians will prescribe until further studies are performed. Edoxaban will almost certainly become the fourth new oral anticoagulant (NOAC)…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Panel Gives Cautious Endorsement to Novel Boston Scientific Device (9 Oct 2014)

News

The FDA’s Circulatory System Devices advisory panel gave an extremely cautious endorsement on Wednesday to Boston Scientific’s Watchman device, a novel catheter-delivered left atrial appendage closure device for people with atrial fibrillation. They signaled that although they thought the device should be made available they also thought that there should be significant restrictions on its use. The panel wrestled…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Boback

Race and Ethnicity Do Not Affect the Benefits of Device Therapy in Heart Failure (11 Sep 2014)

Voices

Boback Ziaeian, MD

Boback Ziaeian discusses his observational study exploring the benefits of guideline-recommended cardiac resynchronization therapy and ICD therapy in heart failure patients, according to race and ethnicity.

Avatar of Seth

An Electrophysiology Service Diagnostic Conundrum (25 Aug 2014)

Cardiology Case Discussion

Seth Shay Martin, MD and James Fang, MD

A 57-year-old woman with paroxysmal atrial fibrillation, long-QT syndrome after ICD implantation, and severe anxiety presents a unique diagnostic challenge.

Avatar of Larry Husten, PHD

Increased Cardiac Risk Linked to Clarithromycin (19 Aug 2014)

News

Acute use of the popular macrolide antibiotic clarithromycin has been linked to a small but significant increase in cardiac death. In a report in the BMJ, researchers in Denmark analyzed the effects over a 14-year period of the acute use of penicillin V, roxithromycin, and clarithromycin. Earlier research raised concerns that marcrolide antibiotics in general, and erythromycin and azithromycin…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Mintu

What’s the Next Phase for Digoxin in Patients with Atrial Fibrillation? (11 Aug 2014)

Voices

Mintu Turakhia, MD MAS

Mintu P. Turakhia discusses his observational study of digoxin use and mortality risk in patients with atrial fibrillation, using data from the TREAT-AF study.

Avatar of Larry Husten, PHD

Study Offers Little Support for an Old Drug (11 Aug 2014)

News

Digoxin is one of the oldest drugs in the cardiovascular arsenal, derived from the foxglove plant and first described in the 18th century by William Withering. It is frequently used in patients with heart failure (HF) and with atrial fibrillation (AF). The few trials supporting its use were performed in HF patients before newer treatments…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.